HCSG
Healthcare Services Group, Inc.
HCSG's fundamentals are strong and it looks cheap: trading at 17x earnings, below its usual 24x. Analysts expect strong earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
HCSG Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Strong |
HCSG's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
HCSG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 17x | $25.02 | — |
| Cheap | 19x | $28.51 | +14% |
| Forward | 21x | $25.02 | — |
| Fair | 24x | $35.09 | +40% |
| Expensive | 35x | $52.32 | +109% |
Historical ranges are pointers, not guarantees.
HCSG's PE is in its cheap range at 17x. On analysts' estimates for next year's earnings, today's price would be 21x.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
HCSG Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
HCSG has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
HCSG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.18 | -20% |
| Q3 2026 | $1.48 | +179% |
| Q2 2026 | $1.71 | +1215% |
| Q1 2026 | $0.95 | +73% |
| Q4 2025 | $0.81 | +53% |
| Q3 2025 | $0.53 | -22% |
| Q2 2025 | $0.13 | -69% |
| Q1 2025 | $0.55 | -1.8% |
| Q4 2024 | $0.53 | +1.9% |
HCSG has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
HCSG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $479.6M | +3.3% |
| Q2 2026 | $470.8M | +2.7% |
| Q1 2026 | $462.8M | +3.4% |
| Q4 2025 | $466.7M | +6.6% |
| Q3 2025 | $464.3M | +8.5% |
| Q2 2025 | $458.5M | +7.6% |
| Q1 2025 | $447.7M | +5.7% |
| Q4 2024 | $437.8M | +3.3% |
HCSG's revenue has grown year over year for 11 quarters in a row: $480M last quarter, up 3.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7% | -5.3 points |
| Q2 2026 | 6.6% | +16 points |
| Q1 2026 | 7.5% | +2.1 points |
| Q4 2025 | 6.1% | +2.7 points |
| Q3 2025 | 12% | +8 points |
| Q2 2025 | -9.1% | -8.7 points |
| Q1 2025 | 5.3% | +0.3 points |
| Q4 2024 | 3.4% | -3.9 points |
HCSG has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over HCSG on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
HCSG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $28.1M | -60% |
| Q2 2026 | $20.2M | -26% |
| Q1 2026 | $42.3M | +64% |
| Q4 2025 | $16M | -54% |
| Q3 2025 | $70M | +2302% |
| Q2 2025 | $27.4M | +83% |
| Q1 2025 | $25.8M | +$54M |
| Q4 2024 | $34.8M | -28% |
HCSG still generates free cash flow, though less than at its 2020 peak: $107M over the past year.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over HCSG on cash flow, with more consistent year-over-year improvement.
HCSG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -526K shares |
| 1 year | -4.9% | -3.6M shares |
| 3 years | -6.7% | -5M shares |
| 5 years | -7.6% | -5.7M shares |
| Available history | -7% | -5.2M shares |
HCSG has 69M diluted shares, down 4.9% from a year ago, with $76M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $11.7M |
| Q2 2026 | $20.9M |
| Q1 2026 | $24M |
| Q4 2025 | $19.6M |
| Q3 2025 | $27.3M |
| Q2 2025 | $7.7M |
| Q1 2025 | $7M |
| Q4 2024 | $1M |
HCSG spent $76M buying back its own shares over the past year, up 77% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over HCSG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
HCSG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | -0.7x | Net Cash |
| Q1 2026 | -1.4x | Net Cash |
| Q4 2025 | -1.5x | Net Cash |
| Q3 2025 | -1.8x | Net Cash |
| Q2 2025 | -2.6x | Net Cash |
| Q1 2025 | -0.9x | Net Cash |
| Q4 2024 | -0.5x | Net Cash |
HCSG has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
HCSG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.1 | Neutral |
| Stochastic | 70.5 | Neutral |
HCSG's weekly RSI is 61 (neutral) and its Stochastic is 71 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
HCSG PE vs Healthcare Sector
| Metric | HCSG | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 26x | 35% below |
| PE % | 6 | 29 | 23 pts below |
HCSG is trading at 17x earnings, a 35% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
HCSG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $22.9 | 9.5% above |
| 20 week MA | $22.9 | 9.4% above |
| 50 week MA | $21.3 | 17% above |
| 100 week MA | $17.5 | 43% above |
| 200 week MA | $14.7 | 71% above |
HCSG has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
HCSG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $24.3 | $27.1 | +11% |
| 2021 | $27.1 | $17.2 | -37% |
| 2022 | $17.2 | $12.2 | -29% |
| 2023 | $12.2 | $10.4 | -15% |
| 2024 | $10.4 | $11.5 | +11% |
| 2025 | $11.5 | $19.6 | +70% |
| 2026 YTD | $19.6 | $25.0 | +27% |
HCSG has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.